Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology
Paola Queirolo, Francesco Spagnolo(Martin University), Alessia Reali, Roberto Patuzzo(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo Bossi(Humanitas University), Michela Cinquini(Mario Negri Institute for Pharmacological Research), Franco Bassetto(University of Padua), Pietro Quaglino(Department of Medical Sciences), Giuseppe Argenziano(Regione Campania), Andrea Boutros(The University of Sydney), Claudio Clemente(IRCCS Policlinico San Donato), Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ketty Peris(Università Cattolica del Sacro Cuore), Vincenzo De Giorgi(Istituto di Chimica Biomolecolare)
Cited by 16
Related Papers
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
|Cancer|2020|1.3k
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|491
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460